New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Eli Lilly and Company

LLY

Healthcare Drug Manufacturers General

Eli Lilly and Company’s revenue for fiscal 2025 (year ended December 2025) was $65.2 billion, up 44.7% from fiscal 2024.

Revenue
+38.6%
EPS
+16.3%
Free cash flow
+21.8%
Total debt
+15.0%

Quarter to September 2026, against a year earlier

1,354.78 3.13 +0.23%
Market cap
$1.27T
P/E
43.9×
Fwd P/E FY26e
42.2×
Dividend yield
0.51%
F-score
7/9
ROIC
26.4%
Net debt / EBITDA
1.2×
Payout ratio
0.2×

Eli Lilly and Company (LLY) Shares outstanding

Alert me on Shares outstanding

Eli Lilly and Company's shares outstanding at the end of fiscal 2025 was $899.3M, unchanged from fiscal 2024. At the end of the quarter to Sep 30, 2026 it was $893.4M. Over the past ten years it has ranged from $899.3M (fiscal 2025) to $1.1B (fiscal 2015) — the current reading is the lowest in ten years. Eli Lilly and Company ranks 12th of 20 Drug Manufacturers General companies by shares outstanding.

Shares outstanding, annual

Embed this chart

Annual newest first

Period Shares outstanding Change
FY2025 $899.3M (0.53%)
FY2024 $904.1M 0.09%
FY2023 $903.3M (0.15%)
FY2022 $904.6M (0.77%)
FY2021 $911.7M (0.09%)
FY2020 $912.5M (2.48%)
FY2019 $935.7M (9.48%)
FY2018 $1.0B (1.74%)
FY2017 $1.1B (0.92%)
FY2016 $1.1B (0.37%)

Quarterly newest first

Period Shares outstanding Change
Sep 2026 $893.4M (0.03%)
Jun 2026 $893.7M (0.25%)
Mar 2026 $895.9M (0.38%)
Dec 2025 $899.3M 0.06%
43 more quarters

Against its own ten years

Low $899.3M High $1.1B
Ten-year median $912.5M
Current reading's percentile 9

Shares outstanding against peers

What Shares outstanding is

Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.

Reported line item

The full definition of Shares outstanding →

More on LLY